Systemic transtiretin amyloidosis in the elderly patient with recurrent pleural effusions

Abstract

Systemic amyloidosis is a group of diseases associated with extracellular deposition of fibrillar proteins, which leads to a loss of normal organ structure and function. Transthyretin amyloidosis occurs with the deposition of amyloid, consisting of transthyretin transport protein, and can be a genetic or degenerative disease of senility (acquired from the deposition of wild-type transthyretin).

The article describes the clinical case of transthyretine amyloidosis in elderly patient, manifested by recurrent pleural effusions and biventricular heart failure demonstrating the complexity of timely diagnosis of wild-type transthyretin amyloidosis.

Keywords

аmyloidosis transthyretinic / chronic heart failure / pleural effusion

References

[1] Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 2014;129(18):1840–1849. DOI: 10.1161/CIRCULATIONAHA.113.006242

[2] Quarta C.C., Solomon S.D., Uraizee I. et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis // Circulation. 2014. Vol. 129, No. 18. P. 1840–1849. DOI: 10.1161/CIRCULATIONAHA.113.006242

[3] Connors LH, Sam F, Skinner M, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational Cohort Study. Circulation. 2016;133(3):282–290. DOI: 10.1161/CIRCULATIONAHA.115.018852

[4] Connors L.H., Sam F., Skinner M. et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational Cohort Study // Circulation. 2016. Vol. 133, No. 3. P. 282–290. DOI: 10.1161/CIRCULATIONAHA.115.018852

[5] Boldueva SA, Petrova VB, Khavinson VKh, et al. Problems in the diagnostics and treatment of transtiretinum amyloidosis with heart disease in the elderly: clinical experience. Advances in Gerontology. 2019;32(1–2):137–144. (In Russ.)

[6] Болдуева С.А., Петрова В.Б., Хавинсон В.Х. и др. Проблемы диагностики и лечения транстиретинового амилоидоза с поражением сердца у лиц пожилого возраста: клинический опыт // Успехи геронтологии. 2019. Т. 32, № 1–2. С. 137–144.

[7] Castaño A, Drachman BM, Judge D, Maurer MS. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev. 2015;20(2):163–178. DOI: 10.1007/s10741-014-9462-7

[8] Castaño A., Drachman B.M., Judge D., Maurer M.S. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs // Heart Fail. Rev. 2015. Vol. 20, No. 2. 163–178. DOI: 10.1007/s10741-014-9462-7

[9] Sultan AM, Edwards WD, Mohammed SF, et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction. Circulation. 2010;122:A17926.

[10] Sultan A.M., Edwards W.D., Mohammed S.F. et al. Cardiac amyloid deposition is common in elderly patients with heart failure and preserved ejection fraction // Circulation. 2010. Vol. 122. P. A17926.

[11] Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232–239. DOI: 10.1080/07853890701842988

[12] Tanskanen M., Peuralinna T., Polvikoski T. et al. Senile systemic amyloidosis affects 25 % of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study // Ann. Med. 2008. Vol. 40, No. 3. P. 232–239. DOI: 10.1080/07853890701842988

[13] Poliakova AA, Semernin EN, Sitnikova MY, et al. Transthyretin amyloidosis in a cohort fold and very old patients with chronic heart failure. Kardiologiia. 2018;58(S2):12–18. (In Russ.). DOI: 10.18087/cardio.2390

[14] Полякова А.А., Семернин Е.Н., Ситникова М.Ю. и др. Транстиретиновый амилоидоз в когорте пациентов с хронической сердечной недостаточностью старческого возраста и долгожителей // Кардиология. 2018. Т. 58, № S2. С. 12–18. DOI: 10.18087/cardio.2390

[15] Dyudina IA. Transtyretin amyloidosis: the current state of the problem. Heart failure and comorbid conditions.2017;1:63–68. (In Ukraine)

[16] Дюдина И.А. Транстиретиновый амилоидоз: современное состояние проблемы // Серцева недостатність та коморбідністани. 2017. N 1. С. 63–68.

[17] Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011;97(1):75–84. DOI: 10.1136/hrt.2009.190405

[18] Dubrey S.W., Hawkins P.N., Falk R.H. Amyloid diseases of the heart: assessment, diagnosis, and referral // Heart. 2011. Vol. 97, No. 1. P. 75–84. DOI: 10.1136/hrt.2009.190405

[19] Fernandes A, Caetano F, Almeida I, et al. Diagnostic approach to cardiac amyloidosis: A case report. Amiloidose cardíaca – a bordagem diagnóstica, a propósito de um casoclínico. Rev Port Cardiol. 2016;35(5):305.e1–305.e7. DOI: 10.1016/j.repc.2016.01.004

[20] Fernandes A., Caetano F., Almeida I. et al. Diagnostic approach to cardiac amyloidosis: A case report. Amiloidose cardíaca – a bordagem diagnóstica, a propósito de um casoclínico // Rev. Port. Cardiol. 2016. Vol. 35, No. 5. P. 305.e1–305.e7. DOI: 10.1016/j.repc.2016.01.004

[21] Lysenko (Kozlovskaya) LV, Rameev VV, Moiseev S, et al. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya. 2020;(1):13–24.(In Russ.). DOI: 10.32756/ 0869-5490-2020-1-13-24

[22] Лысенко (Козловская) Л.В., Рамеев В.В., Моисеев С.В. и др. Клинические рекомендации по диагностике и лечению системного амилоидоза // Клиническая фармакология и терапия. 2020. № 1. С. 13–24. DOI: 10.32756/ 0869-5490-2020-1-13-24

[23] Berk JL. Pleural effusions in systemic amyloidosis. Curr Opin Pulm Med. 2005;11(4):324–328. DOI: 10.1097/01.mcp.0000162378.35928.37

[24] Berk J.L. Pleural effusions in systemic amyloidosis // Curr. Opin. Pulm. Med. 2005. Vol. 11, No. 4. P. 324–328. DOI: 10.1097/01.mcp.0000162378.35928.37

[25] Mansalis KA, Klein DA, Demartini SD, et al. Pleural findings in a patient with persistent pulmonary effusions from systemic amyloidosis. Amyloid. 2011;18(1):29–31. DOI: 10.3109/13506129.2010.537156

[26] Mansalis K.A., Klein D.A., Demartini S.D. et al. Pleural findings in a patient with persistent pulmonary effusions from systemic amyloidosis // Amyloid. 2011. Vol. 18, No. 1. P. 29–31. DOI: 10.3109/13506129.2010.537156

RIGHTS & PERMISSIONS

Boldueva S.A., Evdokimov D.S., Shvets N.S., Shahbazyan A.V., Kalinina E.Y., Mitrofanova L.B.